Earnings ·
Emmaus Life Sciences reported net revenues of $6.3 million for the three months ended June 30, 2026, a 124% increase…
EMMAEmmaus Life Sciences, Inc.
Emmaus Life Sciences reported net revenues of $6.3 million for the three months ended June 30, 2026, a 124% increase from $2.8 million in the prior year period, driven by revenue recognition from an exclusive license agreement with NeoImmuneTech effective May 15, 2026. Operating expenses decreased to $2.1 million from $3.0 million due to the transfer of its sales force to NeoImmuneTech. The company reported a net income of $1.3 million, or $0.02 per share, compared to a net loss of $1.1 million in the same period last year. Cash and cash equivalents stood at $2.8 million as of June 30, 2026. Emmaus Life Sciences is a commercial-stage biopharmaceutical company focused on the treatment of sickle cell disease.